REM392 / ReMYND - LARVOL DELTA

A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants. (clinicaltrials.gov) - P1 | N=19 | Terminated | Sponsor: reMYND | N=72 ➔ 19 | Trial completion date: Jun 2026 ➔ Jun 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Jun 2025; Sponsor decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants. (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: reMYND | Active, not recruiting ➔ Recruiting | N=52 ➔ 72

Enrollment change • Enrollment open

A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants. (clinicaltrials.gov) - P1 | N=52 | Active, not recruiting | Sponsor: reMYND

New P1 trial

Leuven biotech company tests new and improved Alzheimer’s drug (Belga News Agency) - "Leuven-based biotech company Remynd is testing a new and improved drug that could offer hope to Alzheimer’s patients at both early and advanced stages of the disease. The company announced the development in a press release on Wednesday, with initial results expected by early July. The new drug builds on REM0046127, a compound Remynd studied last year....Remynd has now developed a new molecule that works similarly but is designed to avoid these adverse effects. In addition to targeting tau proteins, the improved compound also affects septin proteins, which help regulate calcium balance in brain cells, a process known to be disrupted in Alzheimer’s patients."

New molecule • Alzheimer's Disease